Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PRTC 
PureTech Health PLC (PRTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: PRTC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit -9.14% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 434.89M USD | Price to earnings Ratio - | 1Y Target Price 53.25 |
Price to earnings Ratio - | 1Y Target Price 53.25 | ||
Volume (30-day avg) 2561 | Beta 0.94 | 52 Weeks Range 16.30 - 32.98 | Updated Date 04/6/2025 |
52 Weeks Range 16.30 - 32.98 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -23054.86% |
Management Effectiveness
Return on Assets (TTM) -13.39% | Return on Equity (TTM) -22.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -71897908 | Price to Sales(TTM) 929.25 |
Enterprise Value -71897908 | Price to Sales(TTM) 929.25 | ||
Enterprise Value to Revenue 348.82 | Enterprise Value to EBITDA -51.93 | Shares Outstanding 24018900 | Shares Floating 159411498 |
Shares Outstanding 24018900 | Shares Floating 159411498 | ||
Percent Insiders - | Percent Institutions 1.56 |
Analyst Ratings
Rating 5 | Target Price 53.25 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
PureTech Health PLC
Company Overview
History and Background
PureTech Health PLC is a biotherapeutics company founded in 2005. It focuses on developing medicines to treat serious diseases by creating new biotech ventures based on its own R&D or acquired technologies. Over time, it has evolved from a biotech incubator to a company with clinical-stage programs.
Core Business Areas
- Therapeutics Development: Creation and advancement of novel therapeutic candidates, including small molecules, biologics, and cell therapies.
- Venture Creation: Incubating and launching new biotech companies based on internal discoveries or acquired technologies.
- Clinical Programs: Advancing therapeutic candidates through clinical trials to regulatory approval and eventual commercialization.
Leadership and Structure
The leadership team includes a CEO, CFO, CSO, and other key executives. The organizational structure comprises R&D, clinical development, and business development functions. A board of directors provides oversight.
Top Products and Market Share
Key Offerings
- LYT-100 (Deupirfenidone): A deuterated form of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Market share is currently negligible as it is still in development. Competitors include Genentech (Roche) with Esbriet and Boehringer Ingelheim with Ofev. Revenue N/A, user N/A
- LYT-200: An anti-CD22 antibody being developed for various oncology indications. Market share is currently negligible as it is still in development. Competitors include ADC Therapeutics. Revenue N/A, user N/A
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. It is driven by unmet medical needs and technological advancements.
Positioning
PureTech Health PLC positions itself as an innovator in the biotherapeutics space, focusing on areas with high unmet medical needs. Its competitive advantage lies in its venture creation model and its ability to identify and develop novel therapies.
Total Addressable Market (TAM)
The total addressable market for IPF and oncology indications are billions of dollars. PureTech Health PLC aims to capture a significant share of these markets with its innovative therapies. The TAM for IPF is estimated at $3 billion and for CD22+ cancers over $5 billion. PureTech is still in the development phase, so their current TAM capture is minimal but has a high upside potential.
Upturn SWOT Analysis
Strengths
- Innovative venture creation model
- Strong R&D capabilities
- Experienced management team
- Diverse portfolio of therapeutic candidates
- Strategic partnerships
Weaknesses
- High R&D costs
- Reliance on successful clinical trial outcomes
- Limited revenue streams
- Dependence on external funding
- Long development timelines
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions and partnerships
- Successful clinical trial results
- Regulatory approvals
- Increasing demand for innovative therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expirations
- Economic downturns
Competitors and Market Share
Key Competitors
- Roche Holding AG (RHHBY)
- Boehringer Ingelheim
- ADC Therapeutics SA (ADCT)
Competitive Landscape
PureTech Health PLC's competitive advantage lies in its venture creation model and innovative approach. However, it faces significant competition from established pharmaceutical companies with greater resources and market presence.
Major Acquisitions
Vor Biopharma
- Year: 2021
- Acquisition Price (USD millions): 0
- Strategic Rationale: PureTech Health PLC still holds a significant holding in Vor Biopharma, so they did not acquire the company.
Growth Trajectory and Initiatives
Historical Growth: PureTech Health PLC's growth has been driven by the advancement of its therapeutic candidates and the creation of new ventures.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of its products. Analyst estimates vary depending on clinical trial success.
Recent Initiatives: Recent initiatives include advancing LYT-100 and LYT-200 through clinical trials, expanding its pipeline through strategic partnerships, and exploring new therapeutic areas.
Summary
PureTech Health PLC is a biotech company with a venture creation model focused on developing novel therapies. Its strength lies in its innovative approach and diverse pipeline. However, it faces risks related to clinical trial outcomes and competition. Successful clinical trials and strategic partnerships will be key to its future growth, though its current lack of product revenue raises concerns about sustainability if current trials fail.
Similar Companies
ADCT
ADC Therapeutics SA
ADCT
ADC Therapeutics SA
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PureTech Health PLC
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-11-16 | CEO & Executive Director Dr. Bharatt M. Chowrira J.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 90 | Website https://www.puretechhealth.com |
Full time employees 90 | Website https://www.puretechhealth.com | ||
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.